journal
MENU ▼
Read by QxMD icon Read
search

Lancet Infectious Diseases

journal
https://www.readbyqxmd.com/read/29133171/addressing-antimicrobial-resistance-in-the-uk-and-europe
#1
Victoria Wells, Laura J V Piddock
No abstract text is available yet for this article.
November 10, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29128514/corrections
#2
(no author information available yet)
No abstract text is available yet for this article.
November 8, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29122464/encouraging-results-but-questions-remain-for-dengue-vaccine
#3
In-Kyu Yoon, Stephen J Thomas
No abstract text is available yet for this article.
November 6, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29122463/immunogenicity-and-safety-of-one-versus-two-doses-of-tetravalent-dengue-vaccine-in-healthy-children-aged-2-17-years-in-asia-and-latin-america-18-month-interim-data-from-a-phase-2-randomised-placebo-controlled-study
#4
Xavier Sáez-Llorens, Vianney Tricou, Delia Yu, Luis Rivera, José Jimeno, Ana Cecilia Villarreal, Epiphany Dato, Sonia Mazara, Maria Vargas, Manja Brose, Martina Rauscher, Suely Tuboi, Astrid Borkowski, Derek Wallace
BACKGROUND: Development of vaccines that are effective against all four dengue virus serotypes (DENV-1-4) in all age groups is important. Here, we present 18-month interim data from an ongoing study undertaken to assess the immunogenicity and safety of Takeda's tetravalent dengue vaccine (TDV) candidate over 48 months in children living in dengue-endemic countries. METHODS: We undertook a phase 2, multicentre, randomised, double-blind, placebo-controlled study at three sites in the Dominican Republic, Panama, and the Philippines...
November 6, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29108798/the-unexpected-success-of-nrtis-in-second-line-treatment
#5
Andrew M Hill, Francois Venter
No abstract text is available yet for this article.
November 3, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29108797/lopinavir-plus-nucleoside-reverse-transcriptase-inhibitors-lopinavir-plus-raltegravir-or-lopinavir-monotherapy-for-second-line-treatment-of-hiv-earnest-144-week-follow-up-results-from-a-randomised-controlled-trial
#6
James G Hakim, Jennifer Thompson, Cissy Kityo, Anne Hoppe, Andrew Kambugu, Joep J van Oosterhout, Abbas Lugemwa, Abraham Siika, Raymond Mwebaze, Aggrey Mweemba, George Abongomera, Margaret J Thomason, Philippa Easterbrook, Peter Mugyenyi, A Sarah Walker, Nicholas I Paton
BACKGROUND: Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings...
November 3, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29102520/emergence-of-carbapenem-resistant-hypervirulent-klebsiella-pneumoniae
#7
LETTER
Pengcheng Du, Yuanyuan Zhang, Chen Chen
No abstract text is available yet for this article.
November 1, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29102519/persistent-carbapenem-resistant-klebsiella-pneumoniae-a-trojan-horse
#8
LETTER
Zhi-Qiang Yang, Yong-Lu Huang, Hong-Wei Zhou, Rong Zhang, Kui Zhu
No abstract text is available yet for this article.
November 1, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29102518/emergence-of-carbapenem-resistant-hypervirulent-klebsiella-pneumoniae
#9
LETTER
Hong Yao, Shangshang Qin, Sheng Chen, Jianzhong Shen, Xiang-Dang Du
No abstract text is available yet for this article.
November 1, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29102517/emergence-of-carbapenem-resistant-hypervirulent-klebsiella-pneumoniae
#10
LETTER
Marcus Ho Yin Wong, Hoi-Ping Shum, Jonathan Hon Kwan Chen, Man-Yee Man, Alan Wu, Edward Wai-Chi Chan, Kwok-Yung Yuen, Sheng Chen
No abstract text is available yet for this article.
November 1, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29100899/comparative-pathogenesis-of-rabies-in-bats-and-carnivores-and-implications-for-spillover-to-humans
#11
REVIEW
Lineke Begeman, Corine GeurtsvanKessel, Stefan Finke, Conrad M Freuling, Marion Koopmans, Thomas Müller, Tom J H Ruigrok, Thijs Kuiken
Bat-acquired rabies is becoming increasingly common, and its diagnosis could be missed partly because its clinical presentation differs from that of dog-acquired rabies. We reviewed the scientific literature to compare the pathogenesis of rabies in bats and carnivores-including dogs-and related this pathogenesis to differences in the clinical presentation of bat-acquired and dog-acquired rabies in human beings. For bat-acquired rabies, we found that the histological site of exposure is usually limited to the skin, the anatomical site of exposure is more commonly the face, and the virus might be more adapted for entry via the skin than for dog-acquired rabies...
October 31, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29100898/effectiveness-of-national-and-subnational-infection-prevention-and-control-interventions-in-high-income-and-upper-middle-income-countries-a-systematic-review
#12
REVIEW
Lesley Price, Jennifer MacDonald, Lynn Melone, Tracey Howe, Paul Flowers, Kay Currie, Evonne Curran, Valerie Ness, Debbie Waddell, Sarkis Manoukian, Agi McFarland, Claire Kilpatrick, Julie Storr, Anthony Twyman, Benedetta Allegranzi, Jacqui Reilly
Evidence-based guidance for national infection prevention and control (IPC) programmes is needed to support national and global capacity building to reduce health-care-associated infection and antimicrobial resistance. In this systematic review we investigate evidence on the effectiveness of IPC interventions implemented at national or subnational levels to inform the development of WHO guidelines on the core components of national IPC programmes. We searched CENTRAL, CINAHL, Embase, MEDLINE, and WHO IRIS databases for publications between Jan 1, 2000, and April 19, 2017...
October 31, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29111156/genetics-of-human-susceptibility-to-active-and-latent-tuberculosis-present-knowledge-and-future-perspectives
#13
REVIEW
Laurent Abel, Jacques Fellay, David W Haas, Erwin Schurr, Geetha Srikrishna, Michael Urbanowski, Nimisha Chaturvedi, Sudha Srinivasan, Daniel H Johnson, William R Bishai
Tuberculosis is an ancient human disease, estimated to have originated and evolved over thousands of years alongside modern human populations. Despite considerable advances in disease control, tuberculosis remains one of the world's deadliest communicable diseases with 10 million incident cases and 1·8 million deaths in 2015 alone based on the annual WHO report, due to inadequate health service resources in less-developed regions of the world, and exacerbated by the HIV/AIDS pandemic and emergence of multidrug-resistant strains of Mycobacterium tuberculosis...
October 27, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29107501/corrections
#14
(no author information available yet)
No abstract text is available yet for this article.
October 26, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29102325/surveillance-for-control-of-antimicrobial-resistance
#15
REVIEW
Evelina Tacconelli, Frangiscos Sifakis, Stephan Harbarth, Remco Schrijver, Maaike van Mourik, Andreas Voss, Mike Sharland, Nithya Babu Rajendran, Jesús Rodríguez-Baño
Antimicrobial resistance poses a growing threat to public health and the provision of health care. Its surveillance should provide up-to-date and relevant information to monitor the appropriateness of therapy guidelines, antibiotic formulary, antibiotic stewardship programmes, public health interventions, infection control policies, and antimicrobial development. In Europe, although the European Antimicrobial Resistance Surveillance Network provides annual reports on monitored resistant bacteria, national surveillance efforts are still fragmented and heterogeneous, and have substantial structural problems and issues with laboratory data...
October 25, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29102324/prolonged-versus-short-term-intravenous-infusion-of-antipseudomonal-%C3%AE-lactams-for-patients-with-sepsis-a-systematic-review-and-meta-analysis-of-randomised-trials
#16
Konstantinos Z Vardakas, Georgios L Voulgaris, Athanasios Maliaros, George Samonis, Matthew E Falagas
BACKGROUND: The findings of randomised controlled trials (RCT), observational studies, and meta-analyses vary regarding the effectiveness of prolonged β-lactam infusion. We aimed to identify the effectiveness of prolonged versus short-term infusion of antipseudomonal β-lactams in patients with sepsis. METHODS: We did a systematic review and meta-analysis to compare prolonged versus short-term intravenous infusion of antipseudomonal β-lactams in patients with sepsis...
October 25, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29102323/%C3%AE-lactam-prolonged-infusion-it-s-time-to-implement
#17
Mical Paul, Ursula Theuretzbacher
No abstract text is available yet for this article.
October 25, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29074038/protection-of-the-house-against-chagas-disease-dengue-leishmaniasis-and-lymphatic-filariasis-a-systematic-review
#18
REVIEW
Olaf Horstick, Silvia Runge-Ranzinger
In light of the recent Zika virus outbreak, vector control has received renewed interest. However, which interventions are efficacious and community effective and how to best deliver them remains unclear. Following PRISMA guidelines, we did a systematic review to assess evidence for applied vector control interventions providing protection against Chagas disease, dengue, leishmaniasis, and lymphatic filariasis at the household level. We searched for published literature and grey literature between Jan 1, 1980, and Nov 30, 2015, and updated our search on April 2, 2017, using databases including the Cochrane, Embase, LILACS, PubMed, Web of Science, and WHOLIS...
October 23, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29066132/the-who-public-health-approach-to-hiv-treatment-and-care-looking-back-and-looking-ahead
#19
REVIEW
Nathan Ford, Andrew Ball, Rachel Baggaley, Marco Vitoria, Daniel Low-Beer, Martina Penazzato, Lara Vojnov, Silvia Bertagnolio, Vincent Habiyambere, Meg Doherty, Gottfried Hirnschall
In 2006, WHO set forth its vision for a public health approach to delivering antiretroviral therapy. This approach has been broadly adopted in resource-poor settings and has provided the foundation for scaling up treatment to over 19·5 million people. There is a global commitment to end the AIDS epidemic as a public health threat by 2030 and, to support this goal, there are opportunities to adapt the public health approach to meet the ensuing challenges. These challenges include the need to improve identification of people with HIV infection through expanded approaches to testing; further simplify and improve treatment and laboratory monitoring; adapt the public health approach to concentrated epidemics; and link HIV testing, treatment, and care to HIV prevention...
October 20, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29066131/a-genetically-inactivated-two-component-acellular-pertussis-vaccine-alone-or-combined-with-tetanus-and-reduced-dose-diphtheria-vaccines-in-adolescents-a-phase-2-3-randomised-controlled-non-inferiority-trial
#20
Sirintip Sricharoenchai, Chukiat Sirivichayakul, Kulkanya Chokephaibulkit, Punnee Pitisuttithum, Jittima Dhitavat, Arom Pitisuthitham, Wanatpreeya Phongsamart, Kobporn Boonnak, Keswadee Lapphra, Yupa Sabmee, Orasri Wittawatmongkol, Pailinrut Chinwangso, Indrajeet Kumar Poredi, Jean Petre, Pham Hong Thai, Simonetta Viviani
BACKGROUND: Increasing evidence shows that protection induced by acellular pertussis vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease. We aimed to assess the safety and immunogenicity of a recombinant acellular pertussis vaccine containing genetically inactivated pertussis toxin and filamentous haemagglutinin, as either a monovalent vaccine (aP[PTgen/FHA]) or in combination with tetanus and reduced-dose diphtheria vaccines (TdaP[PTgen/FHA]), versus a licensed tetanus and reduced-dose diphtheria and acellular pertussis combination vaccine (Tdap)...
October 20, 2017: Lancet Infectious Diseases
journal
journal
20187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"